相关实验视频
Updated: Jun 1, 2025

An Ex vivo Model to Study Hormone Action in the Human Breast
Published on: January 8, 2015
在乳腺发育和癌症中的RANK/RANKL信号通路
Gema Pérez-Chacón1, Patricia G Santamaría1, Jaime Redondo-Pedraza1
1Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
用登诺苏马布准RANK通路显示为预防和治疗乳腺癌的前景. 抑制RANKL可能会增强瘤细胞分化,增强免疫反应,并提高对现有疗法的敏感性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- RANK信号通路与乳腺发育和乳腺癌的发病,进展和转移有关.
- 兰克激活影响乳腺细胞增殖,干细胞命运和衰老,其表达与某些乳腺癌亚型的预后不佳有关.
- RANK/RANKL还在瘤微环境中的免疫调节中发挥作用,经常促进免疫抑制.
研究的目的:
- 讨论针对乳腺癌中RANK信号通路的预防和治疗潜力.
- 探索RANK信号对瘤发展的内在和外在影响.
- 审查临床试验调查denozumab用于乳腺癌.
主要方法:
- 对乳腺癌中RANK通路的现有文献的综述.
- 分析RANK/RANKL在瘤细胞生物学和瘤免疫微环境中的作用.
- 描述正在进行和已完成的临床试验涉及denosumab.
主要成果:
- 抑制RANKL可以诱导乳腺瘤细胞分化,并刺激抗瘤免疫反应.
- 失去RANK信号传递可以使乳腺癌细胞对化疗,向治疗 (HER2,CDK4/6抑制剂) 和免疫治疗产生敏感性.
- 德诺苏马布正在临床试验中评估乳腺癌的预防和治疗,包括其免疫调节作用.
结论:
- 准RANK路径为预防和治疗乳腺癌提供了一个有希望的策略.
- 抗RANKL药物丹诺苏马布 (denosumab) 显示出提高治疗效率和调节乳腺癌免疫反应的潜力.
- 目前正在进行进一步的临床评估,以确定RANKL抑制在乳腺癌管理中的全部影响.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Hedgehog Signaling Pathway
Canonical Wnt Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways
Signal Transduction: Overview
Typically, signal transduction involves three...